Abstract: One or more ultrasonic transducers are driven to direct a therapeutic ultrasound signal into tissue. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage abnormal tissue but not harmonically excite healthy tissue.

Abstract: A wearable device includes one or more ultrasonic emitters disposed to direct a therapeutic ultrasound signal into tissue. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite blood clots to liquify the blood clot to become soluble to blood flowing through the head.

Abstract: An anti-tumor agent is provided to a patient to increase a susceptibility of a tumor within the patient to harmonic excitation. Ultrasonic transducers of a wearable are driven to direct a therapeutic ultrasound signal into tissue of the patient. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage the tumor while the anti-tumor agent has increased the susceptibility of the tumor to the harmonic excitation of the therapeutic ultrasound signal.

Abstract: A health message is received. At least one target brain region is selected in response to receiving the health message. An ultrasound modality profile based on the health message and the at least one target brain region is generated. A wearable therapeutic ultrasound device directs the ultrasound beams to the at least one target brain region in response to the health message. The ultrasound beams are driven with the ultrasound beam profile.